Mike Allen, PhD

MSD, UK, Ltd., United Kingdom

Disclosure(s): Merck: I am a full time Merck Employee and own stocks in the retirement plan provided by Merck., Stocks/Bonds (Public Company)

Poster(s):

• (P-1074) Clinical Outcomes in Patients Hospitalized with Exacerbation of Chronic Respiratory Infections treated with Ceftolozane/Tazobactam: Results from SPECTRA
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1076) Describing the clinical characteristics, treatment patterns, and outcomes in hospitalized pneumonia patients treated with Ceftolozane/Tazobactam (C/T): Insights from the SPECTRA Study
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1113) Treatment Patterns and Clinical Outcomes in Hospitalized Patients with Febrile Neutropenia treated with Ceftolozane/Tazobactam: A Subgroup Analysis of the SPECTRA study
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-2305) Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam [C/T] Real-world Analysis Results (SPECTRA): Results of the Immunocompromised Patients
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT